

## SUPPLEMENTARY DATA

### **Lower risk of cancer in patients on metformin in comparison to those on sulfonylurea derivatives: results from a large population – based follow-up study.**

Authors and affiliations: Rikje Ruiten MD <sup>1,2</sup>, Loes E. Visser PharmD <sup>1,3,4</sup>, Myrthe P. P. van Herk – Sukel MSc <sup>5</sup>, Jan-Willem W. Coebergh PhD <sup>6</sup>, Harm R. Haak PhD <sup>7</sup>, P.H. Geelhoed – Duijvestijn PhD <sup>8</sup>, Sabine M.J.M. Straus PhD <sup>9,10</sup>, Ron M.C. Herings PhD <sup>5,11</sup>, Bruno H. Ch. Stricker PhD <sup>1,2,4,10</sup>.

<sup>1</sup> Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands; <sup>2</sup> Drug Safety Unit, Inspectorate of Health Care, The Hague, the Netherlands; <sup>3</sup> Department of Hospital Pharmacy, <sup>4</sup> Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands, <sup>5</sup> PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands; <sup>6</sup> Department of Public Health, Erasmus MC, Rotterdam, The Netherlands, <sup>7</sup> Department of Internal Medicine, Maxima Medical Centre, Eindhoven, The Netherlands; <sup>8</sup> Department of Internal Medicine, Medical Centre Haaglanden, The Hague, The Netherlands; <sup>9</sup> The Dutch Medicines Evaluation Board, The Hague, The Netherlands; <sup>10</sup> Department of Medical Informatics, <sup>11</sup> Department of Health Policy & Management Erasmus MC, Rotterdam, The Netherlands.

Corresponding author: Bruno H. Ch. Stricker, PhD. Erasmus MC, Department of Epidemiology, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands. Tel: +31 10 7044229. Fax +31 10 7044657. E-mail: b.stricker@erasmusmc.nl.

## SUPPLEMENTARY DATA

**Supplementary Figure 1. Adherence Curve:** Drug adherence to sulfonylurea derivatives and metformin of the participants under study.

